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ABSTRACT Immunization with naked genes (DNA-immunization) is a perspective modern approach to prophylactic 
as well as therapeutic vaccination against pathogens, as well as cancer and allergy. A panel of DNA immunogens has 
been developed, some are already in the clinical trials. However, the immunogenicity of DNA vaccines, specifically of 
those applied to humans, needs a considerable improvement. There are several approaches to increase DNA vaccine 
immunogenicity. One approach implies the modifications of the encoded immunogen that change its processing and 
presentation, and thus the overall pattern of anti-immunogen response. For this, eukaryotic expression vectors are 
constructed that encode the chimeric proteins composed of the immunogen and specialized targeting or signal se-
quences. The review describes a number of signals that if fused to immunogen, target it into the predefined subcellular 
compartments. The review gives examples of their application for DNA-immunization.
KEYWORDS DNA-vaccines, МНС-I, MHC-II, antigen presentation.
ABBREVIATIONS ER - endoplasmic reticulum, Ub - ubiquitin, HCV - human hepatitis C virus, ODC - Ornithine decar-
boxylase, RT - HIV-1 reverse transcriptase, CRT - Ca2+-binding protein calreticulin, HVP-16 - human papilloma virus 
16, LAMP-1 - lysosome-associated protein 1, sarsN - nucleocapsid SARS coronavirus protein, LCMV - lymphocytic 
choriomeningitis virus, MHC I - major histocompatibility complex class  I, MHC II - major histocompatibility complex 
class II
INTRODUCTION
One of the most promising vaccine types today are DNA-
vaccines. In its simplest form, a DNA-vaccine is a plasmid 
containing a gene of the pathogenic protein and the elements 
needed to transcribe this gene in mammalian cells. This DNA 
is introduced into mammalian cells during immunization. It 
is then transcribed, and the encoded antigen is synthesized 
initiating an immune response (Fig. 1). Unlike protein-based 
vaccines, DNA-vaccines based on microbial genes and tumor 
antigens have the advantage of synthesizing the specific an-
tigen in the host’s organism, where it is processed correctly 
to induce an immune response of the desired specificity. This 
approach is promising because of the simplicity and low cost 
of the production and transportation of DNA-vaccines as 
compared to the traditional vaccines. Moreover, gene engi-
neering allows an easy modification of DNA-immunogens; 
new antigens can be designed with properties predicted by 
in silico studies. The use of DNA-vaccines causes some anxi-
ety because of the possibility that the genetic material gets 
inserted into the host genome (insertional mutagenesis). How-
ever, the probability of this event is extremely low. It is in 
the range of around 1–7 insertions per 150,000 nuclei, which 
is lower than the rate of the natural insertion mutation by a 
factor of  1,000 [1]. 
DNA-vaccines are used to induce a protective immune 
response against various infections in small animals (ro-
dents) and in larger species [2–4]. Series of trials of pro-
phylactic and therapeutic DNA-vaccines against various 
human pathogens, including HIV-1 and HCV, have been 
performed [5–7]. However, the immunogenicity of genetic 
vaccines needs improvement, especially for human appli-
cations [8–10]. Various approaches are being used in order 
to increase the efficiency of DNA-vaccines [11–13]. They 
include the development of novel methods of DNA-vaccine 
administration (electroporation has become increasingly 
popular in the recent years); supplementing vaccine for-
mulation with cytokines and/or chemokines or their genes 
[14] ; optimizing plasmid vectors by selecting more effective 
gene promoters and regulatory elements [15] ; and modu-
lating plasmid CpG content [14]. The DNA-immunogen is 
also modified: the coding sequence of immunogen is often 
changed to increase the expression [16]. One of the most 54 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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Fig. 1. DNA-immunization 
Table 1. Antigen processing pathways and types of immune responses





of the immune system
Stimulated immune 
response
Inside the cell Proteasome MHC-I CD8+ Cytotoxic 
Outside the cell Lysosome MHC-II CD4+ Cellular, humoral
promising approaches for modifying the immunogen is to 
alter its processing and presentation pathway [17]. Such 
re-direction can be achieved by “labeling” the protein with 
specialized signal sequences. 
This review focuses on the signals directing protein into 
various cellular compartments and their use for DNA-vaccine 
design. In order to be recognized by the immune system, an 
antigen must be processed and presented on the surface of 
a cell by the molecules of the major histocompatibility com-
plex (MHC). There are two main classes of these molecules: 
MHC class I (MHC-I) and MHC class II (MHC-II). In order 
to bind to the molecules of either class, the protein encoded 
by DNA-immunogen must go through antigen processing in 
the specialized cell compartments (Table 1). Endogenous pro-
teins are degraded in the proteasome and are presented in 
a complex with МНС-I on the cell surface, where they can 
be recognized by the receptors of cytotoxic CD8+ T-cells 
(CTL), which then initiate a cytotoxic immune response [18]. 
Exogenous proteins are hydrolyzed by proteases in the lyso-
some, antigen fragments generated by processing are bound 
to MHC-II molecules and recognized by the CD4-receptors 
of T-helper cells, which facilitate cellular as well as humoral 
responses [19]. Thus, it is evident that the processing pathway 
of the immunogen determines the type of immune response 
it induces. 
PRESENTATION OF A DNA-ENCODED 
ANTIGEN VIA THE MHC-I PATHWAY
As has been mentioned earlier, processing of an antigen via 
the MHC-I pathway results in a CTL-response. This process 
involves several steps (Fig. 2). The protein is synthesized in the 
cell and then broken into small peptides in the proteasome, 
after which these fragments are taken up by the transporter-
proteins associated with antigen processing (TAP). These pro-
teins guide the peptides into the endoplasmic reticulum (ER), 
where they can bind to MHC-I molecules [18].
The peptide-MHC-I complex is transported to the cell sur-
face to be recognized by CD8+ T-cells (CTL), manifesting the 
initiation of a cellular response. This is why increasing the 
amount of the protein that is transported into the proteasome 
or ER should in principle increase its presentation via MHC-I 
pathway, hence, the availability on the cell surface resulting 
in an enhancement of the cellular response. 
PROTEASOME-MEDIATED MECHANISM
To be degraded by the proteasome, proteins must bear a 
specific signal – a chain of ubiquitin molecules (Ub), small 
polypeptides consisting of 76 amino acid residues. The eu-
karyotic cell has a specialized group of enzymes that recog-
nize protein substrates and covalently attach polyubiquitin to 
these substrates. This enzymatic group is called the ubiquitin-
conjugating system [20]. 
This system recognizes various proteasome degradation 
signals. Signals can represent a specific amino acid sequence, 
a specific pattern of protein phosphorylation, or alterations 
in the protein structure, often missfolding. Several degra-
dation signals with a characteristic amino acid sequence 
have been described. The first signal discovered was the 
N-degron. This is a specific first amino acid residue in the 
protein that serves as a substrate for the complex of cel-
lular enzymes responsible for labeling the protein with a 
polyubiquitine chain [21]. Amino acids differ in their capac-
ity to be recognized by the ubiquitinating enzymes (Table 2). 
There are also other degradation signals, such as the PEST-
sequence [22] and the Destruction Box [23], often found in 
the short-lived cellular proteins (Table 2).The nature of the 
first amino acid residue in the protein is, thus, one of the 
main protein features determining its accumulation. REVIEWS












Fig. 2. Antigen processing during presentation via the MHC-I pathway
UBIQUITIN-DEPENDENT MECHANISM
The main focus of the researchers has been on the antigen 
(re)targeting into proteasome via the ubiquitin-dependent 
mechanism, thought to provide for antigen processing and 
presentation in complex with MHC-I and an enhanced an-
tigen-specific CTL-response [25–28]. This (re)direction can 
be achieved by cloning an Ub-encoding sequence onto the 
5´-terminus of the target gene and adding a destabilizing 
N-terminal residue after the Ub, which makes an antigen 
a better proteasome substrate. In the cell, Ub is cleaved off 
in a posttranslational modification of the chimeric protein 
catalyzed by the C-terminal ubiquitin hydrolase, thus expos-
ing the N-degron. The HIV-1 nef  was modified in this way 
to generate a Ub-Arg-Nef, which led to the improved im-
munogenicity of nef in mice [29]. Fusion with ubiquitin was 
used for immunization with HIV-1 gene expression libraries. 
All of the ORFs (open reading frames) of HIV-1 encoded by 
32 plasmids were modified by the addition of an ubiquitin 
encoding sequence. After a single immunization using gene 
gun, this library stimulated a strong T-cell response against 
all 32 antigens. This response was registered as an enhanced 
CTL-activity, IFN-γ+ production by CD8+ T-cells and HLA-
tetramer binding [30]. Addition of ubiquitin to the N-termi-
nus of a synthetic protein consisting of HIV CTL-epitopes also 
resulted in the increase of immunogenicity of this prototype 
DNA-vaccine [31].
An incorrect protein folding can also act as the proteasome 
degradation signal. This was used to increase the immuno-
genicity of the influenza virus proteins M1 and NS1. Unstable 
variants of M1 and NS1 were constructed by disrupting their 
alpha-helical regions via introduction of short (foreign) amino 
acid sequences. Immunization by the genes of the destruc-
tured M1 and NS1 resulted in a much stronger CTL-response 
than that induced by the original genes [32]. 
However, for some viral proteins, fusion with the protea-
some-targeting  signals did not result in an increased degra-
dation [27, 33]. The HIV-1 Gag protein modified by ubiqui-
tination and by a destabilizing N-terminal arginine residue 
(Ub-R-Gag) showed only a slight increase in the degradation 
rate. Effective destabilization of this protein required an in-
sertion of the additional exposed lysine residue eK (Ub-R-
eK-Gag). The Ub-R-eK-Gag chimera was effectively direct-
ed into the proteasome, which increased the presentation of 
MHC-I-antigen peptide complexes on the cell surface. How-
ever, this did not significantly increase the anti-Gag CTL-re-
sponse in mouse immunization [34]. Also, no enhancement in 
immunogenic performance was observed after a similar mod-
ification of DNA-immunogen expressing nucleocapsid (core) 
protein of Hepatitis C virus (HCV). HCV core genes carry-
ing cleavable, as well as uncleavable ubiquitin residues with 
N-stabilizing or N-destabilizing amino acid residues, were 
equally poor immunogens [35]. Other (viral) models were de-
scribed for which an increase in the proteasomal degradation 
did not result in an increased protective immunity [34]. 
UBIQUITIN-INDEPENDENT MECHANISM
Notably, some proteins do not require ubiquitin for degra-
dation [36]. The first such protein to be discovered was orni-
thine decarboxylase (ODC) [37]. Its degradation is ATP- and 
antizyme-protein-dependent. The C-terminus of the antizyme 
binds to the N-terminal region of ODC, directing it to the pro-
teasome while the antizyme is released. In addition to the an-
tizyme-binding site on the N-terminus, ODC contains also a C-
terminal PEST-signal [38]. Experiments with deletion mutants 
of ODC have shown that the minimal signal required for the 
rapid degradation of ODC in the proteasome is a 37-residue C-
terminal stretch of amino acids [39]. It was demonstrated that 
this region is required for binding of ODC to the proteasome. 
The ubiquitin-conjugating system is a multi-stage mecha-













Fig. 3. Antigen processing during presentation via the MHC-II pathway 
tion signals, which direct proteins to the proteasome via an 
ubiquitin-independent mechanism, circumvents the effects of 
a multitude of factors and thus provides a more straight-for-
ward way of proteasome targeting. Fusion of HIV-1 reverse 
transcriptase with the minimal proteasome-targeting signals 
of ODC represented by two short amino acid sequences at 
the ODC C-terminus led to an accelerated degradation and 
an increased immunogenicity of the chimeric gene in mice as 
compared to the original gene [40]. This modification was also 
successful when applied to the weakly immunogenic reverse 
transcriptase of drug-resistant HIV-1 [41] helping to enhance 
both cellular and antibody immune responses against the mu-
tant enzyme form [42].
ER-MEDIATED MECHANISM
Processing of an antigen via the МНС-I pathway involves 
the endoplasmic reticulum (ER). That is why increasing the 
antigen’s affinity towards ER can improve the immunogenic 
performance of the antigen. The Ca2+-binding protein cal-
reticulin (CRT) is abundant in ER, where it is associated with 
the components involved in the presentation of the antigen 
via the МНС-I pathway [43- 45]. Fusion of calreticulin to the 
tumor antigens was used to improve the T-cell immune re-
sponse against tumor cells. A DNA-vaccine that encoded a 
fusion of CRT with Е7 protein of human papilloma virus 16 
(HPV-16) was created. Mice immunized by this DNA-immu-
nogen exhibited a significant increase in the population of the 
E7-specific CD8+ T-cells and in their lytic activity against 
E7-expressing tumors [46, 47]. A fusion-protein of CRT with 
another HPV-16 protein E6 also improved the antigen-specif-
ic CD8+ T-cell immune response in mice [48]. 
Altered localization of Е7 HPV-16 protein associated with 
an increased affinity for ER was also achieved by a differ-
ent strategy that involved antigen fusion with the extracel-
lular domain of the Fms-like tyrosine kinase 3 ligand (FL) 
[49]. The E7 gene fusion introduced subcutaneously by the 
gene gun technique led to a considerably increased capac-
ity of E7 to activate specific CD8+ T-cells compared to the 
unmodified Е7 gene. In vitro studies showed that 293 cell 
lines transfected with FL-E7 DNA presented Е7 antigen in 
complex with MHC class I molecules more effectively than 
cells transfected with the original E7 gene. The FL-E7 chi-
mera potently activated CD8+ T-cells; anti-tumor effect 
was dependent on the CD4+Т-cells [49]. Another successful 
case of enhancing the immune response by manipulating the 
ER-signals was reported for the envelope protein E2 of the 
hepatitis C virus. The effect was achieved by duplication of 
the ER-localization sequence, which promoted the accumu-
lation and subsequent release of E2 from the endoplasmic 
reticulum [50]. 
PRESENTATION OF A DNA-ENCODED 
ANTIGEN VIA THE MHC-II PATHWAY
Peptides to be bound to MHC-II are mainly of exogenous ori-
gin and are captured by endocytosis to be directed into the 
lysosomes (Fig. 3). However, it has been demonstrated that 
some intracellular proteins can be presented by MHC-II as a 
result of autophagy [51]. Such proteins are transported into 
the lysosome via the chaperone-mediated transfer carried 
out by a transport-protein; by the engulfment of cytoplasm 
by the lysosome membrane, or by the formation of double-
membrane autophagosomes [51-55]. After transporting to 
the lysosomes, the antigen is cleaved by the acidic proteases 
and the resulting peptides are loaded onto the MHC-II mol-
ecules and brought to the cell surface. On the cell surface, 
these complexes are recognized by the CD4+ T-cell receptors 
[56]. This leads to the  stimulation of cellular (Th1-type) and 
humoral (Th2-type) immunity. REVIEWS
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Table 2. Signals for proteasome degradation with specific amino acid sequences
Name of signal Amino acid sequence
N-degron
N-terminal amino acid (recognizing enzyme):
Destabilizing – F, L, W, Y, I, R, K, H, A, S, T, G (Е3 -ligase); N,Q (N- N,Q (N-terminal hydrolase); 
D,E,C (Arg-t-RNA-transferase) 
Stabilizing – M, S, G, V (no recognizing enzymes)
PEST- sequence Sequence rich in proline (P), glutamic acid (E), serine (S), and threonine (T) 
Destruction box R-A/T-A-L-G-X-I/V-G/T-N
Traditional therapeutic vaccinations with soluble protein 
antigens aim to recruit CD4+ T-cells. The relatively weak 
response of CD4+ T-cells is one of the weak points of DNA-
vaccines today. Clinical trials have also shown that the cur-
rent generation of DNA-vaccines cannot induce a strong 
antibody response [57]. Therefore, targeting of antigen pre-
sentation into the MHC-II pathway in order to activate CD4+ 
Т-cells seems especially advantageous. Such targeting can be 
achieved artificially by supplementing immunogen with lyso-
some localization signals. 
The DNA-antigen can be specifically (re)directed into lyso-
somes using protein sorting signals. Such intracellular sorting 
signals can be found in the cytoplasm-terminal regions of the 
transmembrane and lysosome-associated proteins [24, 58, 59]. 
Most of them are short amino acid sequences and can be di-
vided into the tyrosine- and dileucine-bearing sequences [24, 
60]. Tyrosine-bearing signals have a consensus motif NPXY 
or YXXØ (where X is any amino acid, and Ø is an amino acid 
with a large hydrophobic side-chain). The consensus se-
quence of the dileucine signals is (DE)XXXL(LI) or DXXLL. 
These signals are recognized by the adaptor protein AP or by 
related complexes and are then directed into the trans-Golgi, 
to the plasmatic membrane, and further into the endosomes. 
There are other motifs, such as a cluster of acidic amino acids 
and the NPFSD sequence [58]. A number of cellular proteins 
are directed into lysosomes due to the presence of a phospho-
rylated mannose residue attached to the consensus sequence 
NX(ST) [61–63]. There are also signals that seem to direct 
cytoplasmic proteins into the lysosome via an autophagosome 
mechanism [64].
LYSOSOME-MEDIATED MECHANISM 
It has been shown that tyrosine- and dileucine signals can ef-
fectively direct heterologous proteins into the lysosome [19, 
65, 66]. The most actively used signals targeting to MHC-II 
presentation are those of the lysosome-associated membrane 
protein 1(LAMP-1) [67]; invariant chain (Ii) [65], and the AP3- 
binding motif of the lysosome protein LIMP II [66].
LAMP-1 SIGNAL
Sorting signal of the lysosome-associated protein 1 (LAMP-1) 
targets the antigen to processing via the MHC-II presentation 
pathway and enhances its presentation to CD4+ Т-cells, as 
has been shown in in vitro experiments. Mouse immunization 
experiments have demonstrated that LAMP-1gene chimeras 
induced stronger lymphoproliferative activity, CTL-activity 
and higher antibody titers as compared to the nonmodified 
DNA-immunogens. An increase in the Th2-type immune re-
sponse of CD4+ Т-cells in response to the LAMP-1 fusions 
was shown after immunization with DNA encoding LAMP-1 
fusions of HIV-1 gp160- and p55gag [68, 69]. A LAMP/gag 
DNA-vaccine stimulated prolonged B-, CD4+ and CD8+ 
T-cell responses, while an immune response caused by the 
injection of a nonmodified Gag gene rapidly receded [70]. 
Another successfully redirected cytoplasmic protein was the 
nucleocapsid protein of the coronavirus SARS (sarsN). Immu-
nization of mice with DNA encoding the LAMP-1-sarsN chi-
mera led to a balanced specific IFN- and IL-4 production and 
strong CTL-response against sarsN [66]. Also, fusion of HIV-1 
reverse transcriptase with LAMP-1 improved the immuno-
genicity of a prototype DNA-vaccine against a drug-resistant 
virus. A strong immune response of the mixed Th1/Th2-type 
was raised both against the wild and drug-resistant HIV-1 
reverse transcriptases, circumventing tolerance of the im-
mune system towards this conserved retroviral antigen [71].
Fusion with LAMP-1 increased the immunogenicity of 
DNA immunogens encoding flavivirus envelope proteins. In 
a candidate vaccine against Dengue virus type 2 based on the 
DNA encoding the premembrane (preM) and envelope (E), 
the transmembrane and cytoplasmic domains of E were re-
placed by similar domains of LAMP-1 [72]. LAMP-1/preM-
E chimera exhibited a characteristic granular cytoplasmic 
staining that indicated co-localization with the endogenous 
LAMP-1, MHC-II, and H2-M proteins that was not observed 
in the case of the nonmodified antigen. Mice immunized 
with the gene of the LAMP-1/preM-E chimera exhibited a 
much higher level of neutralizing antibodies than the con-
trols that received the parental preM-E gene. A similar proto-
type DNA-vaccine was designed against the West Nile virus. 
In this case, the premembrane and envelope (WN preM-E) 
coding sequences were fused to the sequences encoding the 
transmembrane and cytoplasmic domains of LAMP-1 [73]. 
Mice immunized by the gene of the WN LAMP-1/preM-E 
chimera responded by a long-lasting production of high titers 
of neutralizing antibodies, while DNA encoding the original 
antigen induced a short-termed low-titer antibody response. 
Altogether, these results provide a basis for creating a panel 
of effective DNA-vaccines against flaviviruses. 
Introduction of the HPV-16 Е7 protein gene, fused to the 
sequence encoding LAMP-1, also increased the Th2-type im-
mune response [74]. Introduction of a secretory variant of E7/
LAMP-1 in the form of a DNA-chimeric recombinant virus 
induced a strong anti-tumor immune response, which pre-
vented the formation of tumors and reduced the size of the 58 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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ones already present [75].
There are, however, few unsuccessful cases of applying 
this modification to the cytoplasmic proteins, as in the case of 
the nucleocapsid protein of HCV and of p53 [35, 76]. A plas-
mid was constructed expressing a chimeric fusion protein of 
HCV nuclecapsid protein with signal- and C-terminal LAMP-
1 sequences. Immunization of mice with this construct did not 
lead to any detectable antibody response or cell proliferation 
and induced only weak CTL-activity [35]. Thus, direction into 
the lysosome by fusing the immunogen to LAMP-1 does not 
necessarily ensure an enhancement of the Th-2 type immune 
response. 
INVARIABLE CHAIN SIGNAL
MHC-II molecules require transportation into the lysosome 
compartment. This transport involves the invariant chain 
of MHC class II molecules (Ii) [77]. Two sorting signals were 
found in the cytoplasmic domain of Ii [65, 77, 78]. It was 
shown that endogenously synthesized proteins, normally not 
presented via the MHC-II pathway, can be effectively pre-
sented by MHC-II if fused to Ii [79]. Numerous experiments 
in the animal models demonstrated that fusion of the recom-
binant antigens to Ii can enhance, broaden, and prolong the 
protective immune response to the resulting chimeric DNA-
vaccines. In vitro and in vivo experiments had shown that 
immunogens based on an adenovirus expressing fusion of Ii 
with the glycoprotein of lymphocytic choriomeningitis virus 
(LCMV) had an increased ability to stimulate LCMV-specific 
CD4+ and CD8+ T-cells. Moreover, mice that had been im-
munized by this plasmid only once were resistant to the infec-
tion by the lethal LCMV dose [80]. 
This approach is also effective for immunization of larg-
er species. A DNA-construct was made encoding the major 
surface protein 1a of Anaplasma marginale fused with the 
lysosome-targeting motif of the bovine Ii, which directed the 
chimera into the lysosome compartment [81]. A single dose 
of this plasmid effectively stimulated an immune response 
seen as a potent proliferation of IFN-γ+/CD4+ T-cells and 
production of specific IgG. A single injection of this construct 
induced antigen specific memory cells, which formed the ba-
sis for an accelerated response to repeated doses of the anti-
gen [81]. 
DIRECTION INTO AUTOPHAGOSOMES
The precise mechanisms behind autophagy are yet unknown 
despite the intensive ongoing studies. With regard to antigen 
retargeting, it was shown that fusion of the autophagosome-
associated protein Atg8/LC3 with the influenza virus matrix 
protein 1 leads to a considerable increase in the MHC class 
II presentation and in the M1-specific response of CD4+ T-
cells [82]. This confirms that autophagy constantly and effec-
tively directs cytoplasmic proteins into presentation via the 
MHC class II pathway, where they can be used to stimulate a 
Т-helper response.
SECRETORY DIRECTION
An effective approach to the induction of a T-helper immune 
response is targeting of proteins for secretion into the extra-
cellular environment. Fusion of HIV-1 Gag and E proteins 
to the secretory chemokine MCP3 directed these viral pro-
teins into the secretory pathway. Chimeric genes induced an 
effective production of anti-HIV-1 antibodies in macaques. 
Macaques immunized with the chimeras and infected with 
a pathogenic SIVmac251 had lower viral loads than the in-
fected naïve animals [83]. This is an example of the conver-
sion of an endogenous antigen into the exogenous, for further 
capture by endocytosis and transfer to the lysosomes. This 
pathway, as well as the endogenous lysosome (re)targeting, 
enhances antigen presentation in complex with the MHC class 
II molecules and can considerably increase the immunogenic-
ity of DNA-vaccines. 
CONCLUSIONS
Today, mankind faces an acute problem of creating vaccines 
against such hazardous diseases as hepatitis C, the immuno-
deficiency caused by HIV-1, and cancer. DNA-vaccine tech-
nology opens a wide range of possibilities for creating effec-
tive vaccines, one such is through immunogen (re)targeting. 
In this paper, we reviewed a number of signal sequences that 
can be introduced into the immunogens to direct them into a 
predetermined processing and presentation pathway, usually 
different from the one they would naturally take. Direction of 
an antigen into the MHC-I presentation pathway would en-
hance the cytotoxic Т-cell response, while direction onto the 
MHC-II pathway would activate T-helper cells and stimulate 
both cellular and humoral responses. Overall, the use of signal 
sequences to control and guide immunogen presentation can 
increase the immunogenic potential of the existing DNA-im-
munogens and help to create new effective prophylactic and 
therapeutic vaccines for diverse human applications.  
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